Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 8/2018

01-08-2018 | Letter

At what price decreased mortality risk?

Response to ‘Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?’

Authors: A.J. Rodriguez, P.R. Ebeling

Published in: Osteoporosis International | Issue 8/2018

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, Graves S, Staples MP, Murphy B (2009) A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 361:557–568CrossRefPubMed
2.
Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, Edwards R, Gray LA, Stout L, Owen S, Hollingworth W, Ghdoke B, Annesley-Williams DJ, Ralston SH, Jarvik JG (2009) A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 361:569–579CrossRefPubMedPubMedCentral
3.
Edidin AA, Ong KL, Lau E, Kurtz SM (2015) Morbidity and mortality after vertebral fractures. Spine (Phila Pa 1976) 40:1228–1241CrossRef
4.
Ong KL, Beall DP, Frohbergh M, Lau E, Hirsch JA (2018) Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials? Osteoporos Int 29:375–383CrossRefPubMed
5.
Joestl J, Lang N, Bukaty A, Tiefenboeck TM, Platzer P (2017) Osteoporosis associated vertebral fractures—health economic implications. PLoS One 12:e0178209CrossRefPubMedPubMedCentral
6.
Laratta JL, Shillingford JN, Lombardi JM, Mueller JD, Reddy H, Saifi C, Fischer CR, Ludwig SC, Lenke LG, Lehman RA (2017) Utilization of vertebroplasty and kyphoplasty procedures throughout the United States over a recent decade: an analysis of the Nationwide Inpatient Sample. J spine Surg (Hong Kong) 3:364–370CrossRef
7.
Clark W, Bird P, Gonski P, Diamond TH, Smerdely P, McNeil HP, Schlaphoff G, Bryant C, Barnes E, Gebski V (2016) Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 388:1408–1416CrossRef
Metadata
Title
At what price decreased mortality risk?
Response to ‘Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty “sham” trials?’
Authors
A.J. Rodriguez
P.R. Ebeling
Publication date
01-08-2018
Publisher
Springer London
Published in
Osteoporosis International / Issue 8/2018
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-018-4550-5

Other articles of this Issue 8/2018

Osteoporosis International 8/2018 Go to the issue

Original Article

Genetic profiling of decreased bone mineral density in an independent sample of Caucasian women

Review

Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies

Letter

Reply to “At what price decreased mortality risk?”

Original Article

Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia—not atypical at all

Original Article

Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway

Original Article

Low rates of osteoporosis treatment after hospitalization for hip fracture in Hawaii